Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6201 Plus Dabrafenib for CNS Metastases from BRAF V600-Mutated Melanoma
NCT05388877Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Oct 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of e6201 in melanoma, sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose. Started Oct 2022; status: terminated.
02
Drugs
e6201
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05388877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388877.